Novartis Allays Concerns Over Cosentyx Sales Miss
The Swiss major has calmed investor fears over the growth trajectory of Cosentyx, maintaining that its move into first-line therapy in ankylosing spondylitis and psoriatic arthritis, as well as psoriasis, will continue to drive sales.
You may also be interested in...
Novartis stresses long-term safety database for Cosentyx – with five years' worth of data in three indications – psoriasis, psoriatic arthritis and ankylosing spondylitis.
The Swiss major is very happy indeed with the growth trajectory of Cosentyx and Entresto and pleased with how its migraine drug Aimovig has started. However the revelation of manufacturing problems with its CAR-T therapy Kymriah marred Novartis' second-quarter results.
Lilly reported positive results for Taltz in a second Phase III study in ankylosing spondylitis and plans to file for FDA approval this year, which would give the IL-17A inhibitor a label similar to its rival Cosentyx, for which Novartis is working hard to build, maintain and grow market share.